TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: decreases in eating disorder symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improvements in psychosocial functioning
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: ventilatory efficiency during peak exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: oxygen consumption at the anaerobic threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: serum levels of urea and creatinine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: interleukin 10 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: sustained virologic response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean change in visual acuity from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of time spent sedentary
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of atherothrombotic stroke
Endpoint domain: Mortality/survival
Primary endpoint: Increase in interleukin-6 concentration in bronchoalveolar lavage fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Increase in alveolar leukocyte count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Increase in tumor necrosis factor-α in bronchoalveolar lavage fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Non-VA hospitalizations for breathing-related problems
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Arousal index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total wrist motion permitted
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sweat gland maximum ion reabsorption rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participation in DXA screening
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: peak knee extensor torque
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: lumbar multifidus thickness changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Mean number of partners
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion reporting unprotected anal sex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean unprotected anal sex episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body weight loss at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body weight loss at 24 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neuropsychological and EEG deficits
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cervical Lateral Flexion Range of Motion (ROM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS score of pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in clinical symptoms of vaginal dryness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: levels of inflammatory mediators
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: leukocyte counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cumulative incidence of ulcers >/=3 mm
Endpoint domain: Adverse events/effects
Primary endpoint: Stone free rate after twelve months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain sensations during stone clearance
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Thyroid-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: ACR20 response at week 16
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median change from baseline in total vdH-S score at week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean dexamethasone concentration in aqueous humor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seizure duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Achievement of A1C <= 7%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Control of postoperative nausea and vomiting (PONV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for rescue antiemetic
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Changes in lipid profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Amplitude of the event-related potential Go P3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Delta power during the CPT-OX
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction of oxidized purines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Reduction of oxidized-LDL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Reduction of C-reactive protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: percentage of alcohol-related condomless sex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Leucopenia (grade III-IV)
Endpoint domain: Adverse events/effects
Primary endpoint: Neurotoxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Change in correct answers
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Wrist function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of risk for advanced adenomas
Endpoint domain: Mortality/survival
Primary endpoint: Duration of block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total effective rate of TCM symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 2-h glucose values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in SGRQ scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of cholangitis
Endpoint domain: Adverse events/effects
Primary endpoint: freedom from PSA failure
Endpoint domain: Mortality/survival
Primary endpoint: Treatment success rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nitric oxide levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peroxynitrite levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Na+/K+‐ATPase activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: oral plasma clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: apparent volume of distribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relative bioavailability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: first HF hospitalization or death
Endpoint domain: Mortality/survival
Primary endpoint: Bioavailability of ketamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Norketamine/ketamine area under the plasma concentration-time curve ratios
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cerebral oxygenation (SjO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Desaturation (SjO2 <= 50%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of naltrexone induction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment retention over 12 weeks
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Risk of dropping out
Endpoint domain: Adverse events/effects
Primary endpoint: Agreement between computer program and chart review for drug requiring TDM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of the computer program
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of the computer program
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of death or severe congestive heart failure
Endpoint domain: Mortality/survival
Primary endpoint: Mortality rate after one year
Endpoint domain: Mortality/survival
Primary endpoint: EQ-5D utility index
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: ACh-dependent increase in FBF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of sore throat and hoarseness
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage fat mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: EPA levels in erythrocyte membranes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: DHA levels in serum phospholipids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Operative time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first progression of disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ventilatory response to hypercapnia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Ventilatory response to hypoxia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Weight gain velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Linear growth faltering (LAZ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of new T2 lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Gd+ lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: annualized relapse rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Utilization of complementary and alternative medicine (CAM)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Intention to use moxibustion in subsequent pregnancy
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in hip circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fasting triglycerides reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postprandial triglycerides reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in soluble vascular cell adhesion molecule-1 (VCAM-1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: overall psychopathology improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: negative symptoms improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: positive symptom outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Image quality of spiral brain scans
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correct identification of patients with multiple providers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correct identification of overlapping opioid and benzodiazepine prescriptions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correct identification of high daily dosages of opioids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Willingness to participate in future HIV vaccine trials
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Post-vaccination geometric mean titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seroresponses to A components
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preference for administration method
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: mean sick leave duration per patient
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: total costs per patient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: disability scale effectiveness
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: First-time insertion success rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ventilation success rates after carboperitoneum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Willingness to interact with stimulus images
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Level of MDA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of Hcy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activity of SOD and EC-SOD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiac Index (CI) after 30 min of support
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: IIEF erectile function (EF) domain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of successful intercourse attempts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of patients reporting improved erections
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discomfort score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean pain score after injections
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: complete response and remission
Endpoint domain: Mortality/survival
Primary endpoint: Decrease in SSF volumes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall quality score of reports
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: live delivery rates
Endpoint domain: Mortality/survival
Primary endpoint: miscarriage rates
Endpoint domain: Mortality/survival
Primary endpoint: Interobserver agreement for categorizing stenoses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Degree of certainty and overall quality score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cytomegalovirus infection
Endpoint domain: Adverse events/effects
Primary endpoint: New-onset diabetes posttransplant
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients achieving ASAS40
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ankylosing Spondylitis Disease Activity Score - C-reactive protein (CRP) inactive disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Work Productivity and Activity Impairment Questionnaire percent impairment while working
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: overall psychological distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Deliveries before 34 weeks of gestation
Endpoint domain: Mortality/survival
Primary endpoint: sum score of quality-of-care indicators
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Episodic memory performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Flexural strength values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Range of movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Onset time for sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: movement duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Improvements in pain (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvements in health-related quality of life (SF-12)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Reduction of postural tremor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Regression of Cornell product LVH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Regression of Sokolow-Lyon voltage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: lipid levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fluoride retention in lased enamel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean reduction in total Yale‐Brown Obsessive Compulsive Scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Obsession-free interval for the Yale‐Brown Obsessive Compulsive Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Drug resistance rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in median glomerular filtration rate (eGFR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Mean creatinine level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: extension ROM improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6MWT physical capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative rate of the surgical margin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Minimum ADC ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in total symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PAQLQ score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in ECG measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of fat mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinically meaningful decline in FACT-LCS at 3 months
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Conservation of primary teeth with periradicular lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SEBT composite score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Efficacy Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Marked Efficacy Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abatement of distention and fullness of stomach
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Sedation adequacy score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discomfort during emergence from sedation
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of sore throat and hoarseness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of buckling during extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: fluctuation of HR and BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 7-event cardiovascular disease composite
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time with intracranial pressures above treatment threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Days in the intensive care unit (ICU)
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Scores on the Extended Glasgow Outcome Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: microleakage at interface
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adhesive bond strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in proteinuria levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in serum albumin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tiselius risk index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: urinary calcium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: relative supersaturation of brushite
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Glycemic control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes